UMUlrich Matzner

Ulrich Matzner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ulrich Matzner has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Volkmar Gieselmann

    Rheinische Friedrich-Wilhelms University, Institute of Biochemistry and Molecular Biology, Nussallee 11, D-53115 Bonn, Germany

    6 shared publications
  • Frank Matthes

    Cardiovascular Research–Translational Studies, Lund University, Malmö, Sweden

    5 shared publications
  • Jens Fogh

    Zymenex A/S, Roskildevej 12C, DK-3400 Hillerød, Denmark

    5 shared publications
  • Annika Böckenhoff

    Institute of Biochemistry and Molecular Biology, Rheinische Friedrich-Wilhelms Universität, D-53115 Bonn, Germany; and Institute of Biochemistry, Westfälische Wilhelms-Universität, D-48149 Münster, Germany

    2 shared publications
  • Claes Andersson

    Zymenex A/S, Dalénum 13, S-18170 Lidingö, Sweden

    2 shared publications
  • Claudia Wohlenberg

    Institute of Biochemistry and Molecular Biology, Rheinische Friedrich-Wilhelms Universität, D-53115 Bonn, Germany; and

    2 shared publications

Latest Publications

  • Enzyme replacement therapy of a novel humanized mouse model of globoid cell leukodystrophy

    by Frank Matthes, Claes Andersson, Axel Stein, Carl Eistrup, Jens Fogh, Volkmar Gieselmann, David A. Wenger, Ulrich Matzner


  • Open Access

    Comparison of Five Peptide Vectors for Improved Brain Delivery of the Lysosomal Enzyme Arylsulfatase A

    by Annika Böckenhoff, Sandra Cramer, Philipp Wölte, Simeon Knieling, Claudia Wohlenberg, Volkmar Gieselmann, Hans-Joachim Galla, Ulrich Matzner

    Enzyme replacement therapy (ERT) is a treatment option for lysosomal storage disorders (LSDs) caused by deficiencies of soluble lysosomal enzymes. ERT depends on receptor-mediated transport of intravenously injected recombinant enzyme to lysosomes of patient cells. The blood–brain barrier (BBB) prevents efficient transfer of therapeutic polypeptides from the blood to the brain parenchyma and thus hinders effective treatment of LSDs with CNS involvement. We compared the potential of five brain-targeting peptides to promote brain delivery of the lysosomal enzyme arylsulfatase A (ASA). Fusion proteins between ASA and the protein transduction domain of the human immunodeficiency virus TAT protein (Tat), an Angiopep peptide (Ang-2), and the receptor-binding domains of human apolipoprotein B (ApoB) and ApoE (two versions, ApoE-I and ApoE-II) were generated. All ASA fusion proteins were enzymatically active and targeted to lysosomes when added to cultured cells. In contrast to wild-type ASA, which is taken up by mannose-6-phosphate receptors, all chimeric proteins were additionally endocytosed via mannose-6-phosphate-independent routes. For ASA-Ang-2, ASA-ApoE-I, and ASA-ApoE-II, uptake was partially due to the low-density lipoprotein receptor-related protein 1. Transendothelial transfer in a BBB cell culture model was elevated for ASA-ApoB, ASA-ApoE-I, and ASA-ApoE-II. Brain delivery was, however, increased only for ASA-ApoE-II. ApoE-II was also superior to wild-type ASA in reducing lysosomal storage in the CNS of ASA-knock-out mice treated by ERT. Therefore, the ApoE-derived peptide appears useful to treat metachromatic leukodystrophy and possibly other neurological disorders more efficiently.


  • Open Access

    Efficacy of enzyme replacement therapy in an aggravated mouse model of metachromatic leukodystrophy declines with age

    by Frank Matthes, Stijn Stroobants, Debora Gerlach, Claudia Wohlenberg, Carsten Wessig, Jens Fogh, Volkmar Gieselmann, Matthias Eckhardt, Rudi D'Hooge, Ulrich Matzner

    Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by a functional deficiency of arylsulfatase A (ASA). Previous studies in ASA-knockout mice suggested enzyme replacement therapy (ERT) to be a promising treatment option. The mild phenotype of ASA-knockout mice did, however, not allow to examine therapeutic responses of the severe neurological symptoms that dominate MLD. We, therefore, generated an aggravated MLD mouse model displaying progressive demyelination and reduced nerve conduction velocity (NCV) and treated it by weekly intravenous injections of 20 mg/kg recombinant human ASA for 16 weeks. To analyze the stage-dependent therapeutic effects, ERT was initiated in a presymptomatic, early and progressed disease stage, at age 4, 8 and 12 months, respectively. Brain sulfatide storage, NCV and behavioral alterations were improved only in early, but not in late, treated mice showing a clear age-dependent efficacy of treatment. Hematopoietic stem cell transplantation (HSCT) for late-onset variants is the only therapeutic option for MLD to date. ERT resembles a part of the HSCT rationale, which is based on ASA supply by donor cells. Beyond ERT, our results, therefore, corroborate the clinical observation that HSCT is only effective when performed in early stages of disease.


  • Open Access

    Transport of Arylsulfatase A across the Blood-Brain Barrier in Vitro

    by Frank Matthes, Philipp Wölte, Annika Böckenhoff, Sabine Hüwel, Mareike Schulz, Pia Hyden, Jens Fogh, Volkmar Gieselmann, Hans-Joachim Galla, Ulrich Matzner


  • Open Access

    Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy

    by Stijn Stroobants, Debora Gerlach, Frank Matthes, Dieter Hartmann, Jens Fogh, Volkmar Gieselmann, Rudi D'Hooge, Ulrich Matzner

    Arylsulfatase A (ASA) catalyzes the desulfation of sulfatide, a major lipid component of myelin. Inherited functional deficiencies of ASA cause the lysosomal storage disease (LSD) metachromatic leukodystrophy (MLD), which is characterized by intralysosomal accumulation of sulfatide, progressive neurological symptoms and early death. Enzyme replacement therapy (ERT) using intravenous injection of active enzyme is a treatment option for many LSDs as exogenous lysosomal enzymes are delivered to lysosomes of patient's cells via receptor-mediated endocytosis. Efficient treatment of MLD and other LSDs with central nervous system (CNS) involvement is, however, hampered by the blood–brain barrier (BBB), which limits transfer of therapeutic enzymes from the circulation to the brain parenchyma. To bypass the BBB, we infused recombinant human ASA (rhASA) by implanted miniature pumps into the cerebrospinal fluid (CSF) of a conventional and a novel, genetically aggravated ASA knockout mouse model of MLD. rhASA continuously delivered to the lateral ventricle for 4 weeks penetrated the brain parenchyma and was targeted to the lysosomes of brain cells. Histological analysis revealed complete reversal of lysosomal storage in the infused hemisphere. rhASA concentrations and sulfatide clearance declined with increasing distance from the infusion site. Correction of the ataxic gait indicated reversal of central nervous system dysfunctions. The profound histopathological and functional improvements, the requirement of low enzyme doses and the absence of immunological side effects suggest intracerebroventricular ERT to be a promising treatment option for MLD and other LSDs with prevailing CNS disease.


  • Site-specific analysis of N-linked oligosaccharides of recombinant lysosomal arylsulfatase A produced in different cell lines

    by Stephan Schröder, Frank Matthes, Pia Hyden, Claes Andersson, Jens Fogh, Sven Müller-Loennies, Thomas Braulke, Volkmar Gieselmann, Ulrich Matzner

    Metachromatic leukodystrophy (MLD) is a lysosomal storage disease caused by a deficiency of the lysosomal enzyme arylsulfatase A (ASA). Enzyme replacement therapy (ERT) is a therapeutic option for MLD and other lysosomal disorders. This therapy depends on N-linked oligosaccharide-mediated delivery of intravenously injected recombinant enzyme to the lysosomes of patient cells. Because of the importance of N-linked oligosaccharide side chains in ERT, we examined the composition of the three N-linked glycans of four different recombinant ASAs in a site-specific manner. Depending on the culture conditions and the cell line expressing the enzyme, we detected a high variability of the high-mannose-type N-glycans which prevail at all glycosylation sites. Our data show that the composition of the glycans is largely determined by substantial trimming in the medium. The susceptibility for trimming is different for the glycans at the three N-glycosylation sites. Interestingly, which of the glycans is most susceptible to trimming also depends on production conditions. CHO cells cultured under bioreactor conditions yielded recombinant ASA with the most preserved N-glycan structures, the highest mannose-6-phosphate content and the highest similarity to non-recombinant enzyme. Notably, roughly one-third of the N-glycans released from the three glycosylation sites were fucosylated. In the last years, numerous recombinant lysosomal enzymes were used for preclinical ERT trials. Our data show that the oligosaccharide structures were very different in these trials making it difficult to draw common conclusions from the various investigations.